Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Glaukos Submits IDE Application to FDA to Study iStent infinite Trabecular Micro-Bypass System - Medical Product Outsourcing
Regulatory

Glaukos Submits IDE Application to FDA to Study iStent infinite Trabecular Micro-Bypass System

Three-stent device is designed to reduce IOP in refractory glaucoma patients.

Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) seeking authorization to study its iStent infinite Trabecular Micro-Bypass System.
 
The iStent infinite is designed for use as a standalone procedure to reduce elevated intraocular pressure (IOP) in refractory glaucoma patients. It includes three heparin-coated titanium stents preloaded into an auto-injection system that allows the surgeon to inject stents across a span of five to six clock hours around Schlemm’s canal, the eye’s primary drainage channel. Once in place, the stents are designed to lower IOP by restoring the natural, physiological outflow of aqueous humor.
 
“We look forward to working cooperatively with the FDA as they review our IDE application

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters